Abstract: The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor.

Abstract: The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action.

Abstract: The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein Bonds a-d, Ring A, R1, R1?, R2, R2?, R3-R8, and n are as defined in the present specification.

Abstract: The present invention provides a drug capable of preventing or treating diabetic nephropathy. The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RAR? agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.

Abstract: A syringe and a syringe set are provided. The syringe can be readily distinguished from other syringes only by viewing a tip of the syringe. The syringe includes a tip provided at an end of a barrel body to be filled with a medicine and having an outer diameter of 4.315 mm to 6 mm, a peripheral wall provided around the tip concentrically with the tip, and a helical rib formed on an inner the of the peripheral wall or an outer face of the tip.

Abstract: Disclosed is a hemostatic agent applicator capable of effectively placing a fluid hemostatic agent on an incision surface. The present invention is a hemostatic agent applicator for use in disposing a fluid hemostatic agent, including a tool body in which a hollow part surrounded by a wall part is formed and which includes an open end part on a downstream side of the wall part, and an inlet provided to a portion of the wall part of the tool body to communicate with the hollow part. This hemostatic agent applicator is useful in medical settings relating to surgical procedures, particularly for surface bleeding of a liver and internal organ surgery such as a spleen and fibroid enucleation. An applicator further reduced in size can be applied not only in abdominal surgery, but in endoscopic surgery as well.

Abstract: It was found that when measuring HMGB1 in samples using antibodies that bind to both HMGB2 and HMGB1, the reaction between HMGB2 and HMGB1 antibodies can be suppressed by coexisting HMGB2 absorbents (HMGB2 antibodies and/or HMGB2-derived peptides that inhibit the binding between HMGB2 and HMGB1 antibodies). More specifically, it was revealed that HMGB1 alone in samples can be measured or detected by contacting the samples with HMGB1 antibodies in the presence of HMGB2 absorbents.

Abstract: A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 ?m.

Abstract: The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.

Abstract: A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum.

Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.

Abstract: The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.

Abstract: This invention relates to an adenovirus vector having excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells. This adenovirus vector derives from the adenovirus type 35 genome by at least partial or total deletion of the E1 region therefrom. The adenovirus vector according to this invention has excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells, ES cells, pluripotent stem cells, blood stem cells, and tissue stem cells.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.

Abstract: Provided is a composition for embryo culture, which contains a constitution suitable for embryo culture. Provided is a composition for embryo culture, which contains (a) a constitution shown in Table A below. TABLE A Components mM L-Alanine 0.297 ± 0.089 L-Asparagine 0.015 ± 0.005 L-Aspartic acid 0.120 ± 0.036 L-Glutamic acid 0.550 ± 0.165 Glycine 0.979 ± 0.294 L(?)-Proline 0.105 ± 0.032 L-Serine 0.176 ± 0.053 L(+)-Arginine 0.108 ± 0.032 L(?)-Cystine 0.048 ± 0.014 L-Histidine 0.053 ± 0.016 L(+)-Isoleucine 0.036 ± 0.011 L-Leucine 0.081 ± 0.024 L(+)-Lysine 0.176 ± 0.053 L-Methionine 0.022 ± 0.007 L(?)-Phenylalanine 0.045 ± 0.013 L(?)-Threonine 0.109 ± 0.033 L-Tryptophan 0.018 ± 0.005 L-Tyrosine 0.048 ± 0.014 L-Valine 0.108 ± 0.032 L-Glutamine or 0.398 ± 0.119 glutamine derivative Taurine 1.412 ± 0.

Abstract: An airway is secured without obstructing sleep even when the lingual radix falls into the airway. An airway expansion apparatus is configured to include a pillow portion that supports a cranial portion, a pair of left and right mandible holding portions that hold the mandible coupled to the cranial portion at the temporomandibular joint, a first actuation mechanism that causes the mandible holding portions to come into contact with the mandible, and a second actuation mechanism that lifts the mandible holding portions with respect to the pillow portion with the mandible holding portions kept in contact with the mandible, in which the mandible is kept lifted.

Abstract: Disclosed is a hemostatic agent applicator capable of effectively placing a fluid hemostatic agent on an incision surface. The present invention is a hemostatic agent applicator for use in disposing a fluid hemostatic agent, including a tool body in which a hollow part surrounded by a wall part is formed and which includes an open end part on a downstream side of the wall part, and an inlet provided to a portion of the wall part of the tool body to communicate with the hollow part. This hemostatic agent applicator is useful in medical settings relating to surgical procedures, particularly for surface bleeding of a liver and internal organ surgery such as a spleen and fibroid enucleation. An applicator further reduced in size can be applied not only in abdominal surgery, but in endoscopic surgery as well.

Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.

Abstract: An objective of the present invention is to provide the cytolethal distending toxin (CDT) of C. hyointestinalis and polynucleotides encoding it, and novel methods for detection of C. hyointestinalis using the cdt genes. The present inventors focused on the cytolethal distending toxin (CDT) of Campylobacter bacteria, and detected the cdt genes of a Campylobacter-like bacterium isolated from an enteritis patient in Thailand. The present inventors discovered a bacterial strain whose cdtB gene was amplified by common primers in C. jejuni, C. coli, and C. fetus, but not by multiplex PCR that can specifically detect the cdtA, cdtB, and cdtC genes of the three bacterial species. The bacterial strain was identified as C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.